Goede V, Fischer K, Dyer MJS, et al. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. EHA 2018; abstract S151.
Ibrutinib-venetoclax bij CLL leidt vaker tot niet-detecteerbare MRD
sep 2025 | Leukemie